logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)CAS 290297-26-6

2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)CAS 290297-26-6

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 290297-26-6

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:

2-[3

,

5-bis(trifluoromethyl)phenyl]-N

,

2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)

,

CAS 290297-26-6 2-[3

,

5-bis(trifluoromethyl)phenyl]-N

,

2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)

CAS NO::
290297-26-6
Appearance::
Solid
Molecular Formula::
C30H32F6N4O
Molecular Weight::
578.59200
EINECS NO::
NA
MDL NO::
MFCD25976831
CAS NO::
290297-26-6
Appearance::
Solid
Molecular Formula::
C30H32F6N4O
Molecular Weight::
578.59200
EINECS NO::
NA
MDL NO::
MFCD25976831
2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)CAS 290297-26-6

Product Description:

Product Name:

2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide CAS NO: 290297-26-6

 

 

Synonyms:

Netupitan;

Netupitant;

UNII-7732P08TIR;

 

 

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.0%

Density: 1.255

Boiling Point: 597.4℃ at 760 mmHg

Flash Point: 315.1℃

Refractive Index: 1.539

Vapor Pressure: 3.09E-14mmHg at 25℃

storage temp.: Sealed in dry,2-8℃

 

 

Netupitant is an antiemitic drug. In the United States, the combination drug netupitant/palonosetron (trade name Akynzeo) is approved by the Food and Drug Administration for prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin. In Europe, it is approved by the European Medicines Agency for the same indication.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.